Electromagnetic frequencies (EMF) that are generated from different electronic devices can interact with biological systems including humans. Several theories described the effects of EMF on the growth of in vitro cancer cell lines and biological systems, which revealed that EMF could inhibit cancer cell growth or decrease viability depending on the field strength and frequency. Accordingly, in this study, we are targeting to assess the effect of the anticancer-extracted electromagnetic spectrums on the growth of two types of cell lines which are the breast cancer cell line MCF-7 and human embryonic kidney HEK293 as a control cell line. Drugs digitalized electromagnetic spectrums of a mixture of anticancer medications were generated using a DigiConPro® VITATEC device emitted using the supplied antenna and applied to a 96-well culture plate containing MCF-7 and HEK293. The cell viability was performed by MTT assay after three days. The post-exposure effect of anticancers' electromagnetic spectrums was determined on the cancer cell line. Anticancers’ electromagnetic spectrums were seen to cause a statistically significant (p<0.05) decrease in the growth rate relative to the control after three days of exposure to the electromagnetic spectrums. Three doses of anticancers’ electromagnetic spectrums were applied as a dose per day, and each dose was running for 5 hours which induced a reduction in MCF-7 growth compared to the control group, while the HEK293 showed no statistically significant decrease in the growth rate. As a conclusion, electromagnetic spectrums of the anticancer medications may have the same effect as the chemical compound.
This study evaluated whether medication-derived electromagnetic waves (MEMW) generated from a combination of clinically used cardiovascular drugs could produce early cardiomyogenic responses comparable to direct medication exposure in human adipose-derived stem cells (ADSCs). ADSCs were assigned to untreated control, direct-medication (salbutamol, ivabradine, valsartan, and sacubitril), or corresponding MEMW exposure groups. After 21 days, cellular morphology, crystal violet staining, and quantitative reverse-transcription PCR were assessed. Both intervention groups showed modest changes from randomly oriented fibroblast-like morphology toward more elongated and aligned arrangements. POU5F1 (OCT4), SOX2, and NANOG expression decreased, whereas the early cardiac-associated markers GATA4, NKX2-5, and NPPA increased. Changes in the late markers TNNI3 and MYH6 were smaller, indicating early cardiomyogenic commitment rather than mature cardiomyocyte differentiation. MEMW exposure therefore produced selected biological responses that broadly paralleled direct medication treatment under the conditions tested. Independent signal characterization, sham controls, protein-level validation, and functional assays are required before mechanistic or translational conclusions can be drawn.
14 October 2026 in Cancer Treatment and Research Communications
In this study, we investigated the effects of medication electromagnetic waves (MEMW) derived from the anticancer drug doxorubicin on tumor growth of MDA-MB-231 breast cancer cell line in a mouse model. Building on prior research, we explored how MEMW inhibits cancer cell proliferation without the toxic side effects associated with traditional chemotherapy. Twenty female nude mice were xenografted with MDA-MB-231 cells and divided into five groups: a control group, a group treated with doxorubicin only, a group treated with doxorubicin plus MEMW, a group treated with MEMW only, and a group treated with MEMW and topical application of olive oil previously exposed to MEMW. Tumor growth was monitored for 21 days. One-way ANOVA tests were used. Significant reductions in tumor growth rate were observed in all treated groups compared to the control group (p < 0.05). The group treated with doxorubicin and MEMW in combination exhibited the highest reduction (85%). While elevated serum AST levels indicated liver toxicity in the groups treated with doxorubicin, the normal AST levels in those treated with MEMW only suggest an improved therapeutic profile. Histopathological evaluation revealed cytotoxic effects and enhanced necrosis in the groups that received combination treatment, while immunohistochemical assays indicated reduction in proliferative activity. Gene expression analysis confirmed that doxorubicin upregulated pro-apoptotic Bcl-2-associated X protein (BAX), while proliferating cell nuclear antigen (PCNA) was downregulated, aligning with histopathological findings., the results present a novel, non-invasive treatment approach based on MEMW, which may offer a promising alternative for cancer therapy by minimizing toxicity while effectively targeting tumor growth.